Analyst Research

Report Title Price
Provider: Wright Reports
Provider: Reuters Investment Profile
Provider: Edison Investment Research
Provider: GlobalData

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Orexo AB Announces Aprroval of Abstral in Japan

Friday, 20 Sep 2013 03:24am EDT 

Orexo AB announced the approval of Abstral (fentanyl) sublingual tablets in Japan, where the product has been registered and will be sold by Kyowa Hakko Kirin Co., Ltd. Based on the agreement, the approval will trigger a payment to Orexo. Kyowa Hakko Kirin and its subsidiaries have the rights for Abstral in all markets except the United States, where the rights are held by Galena Biopharma, Inc. In Japan, Abstral will be distributed jointly by Kyowa Hakko Kirin and Hisamitsu Pharmaceutical Co., Inc. 

Company Quote

5.25 +4.54%
11 Jul 2014